2 clinics shown
Cedar Haven operates a mental health service facility on Morrow Street North in Mena, Arkansas. The practice provides outpatient psychiatric care for adults in the Polk County region. Specific treatment modalities, including whether TMS, esketamine, or ketamine therapies are offered, are not detailed in available information; prospective patients should contact the clinic to confirm service offerings and insurance acceptance.
Mena Regional Health System operates a general hospital on Morrow Street in Mena, providing inpatient and outpatient medical services to residents of western Arkansas. The facility includes a pharmacy and standard hospital departments. Specific psychiatric or procedural mental health services such as TMS therapy, esketamine, or ketamine treatments are not detailed in available information; patients seeking these interventions should contact the hospital directly to confirm whether behavioral health specialists or treatment-resistant depression protocols are offered on-site.
Spravato is the brand name for esketamine, an FDA-approved nasal spray for treatment-resistant depression and major depressive disorder with suicidal ideation. It's derived from ketamine and works on the brain's glutamate system — a different mechanism than traditional antidepressants like SSRIs.
Treatment is administered only at REMS-certified clinics under direct medical supervision. Patients self-administer the spray under a clinician's guidance, then remain at the clinic for at least two hours of monitoring after each dose. The induction phase typically involves twice-weekly sessions for four weeks, followed by weekly or biweekly maintenance dosing depending on response.
Many patients report meaningful symptom improvement within the first one to two weeks — substantially faster than the 4 to 8 weeks typical of oral antidepressants. Spravato is taken alongside an oral antidepressant, not as a replacement.
The most common side effects are dissociation, dizziness, sedation, and elevated blood pressure during and shortly after dosing. These typically resolve within the two-hour monitoring window. Patients cannot drive on the day of treatment.
Most commercial insurance and Medicare cover Spravato for treatment-resistant depression with prior authorization. Clinics offering Spravato in our directory hold active REMS certification and are staffed to provide the required in-clinic monitoring period.